Brief: Zynerba Pharmaceuticals Announces The Completion Of Enrollment In The Pivotal Connect-FX Trial Of Zygel In Fragile X Syndrome
26/02/2020 12:45
Feb 26 (Reuters) - Zynerba Pharmaceuticals Inc ZYNE.O :
* ZYNERBA PHARMACEUTICALS ANNOUNCES THE COMPLETION OF
ENROLLMENT
IN THE PIVOTAL CONNECT-FX TRIAL OF ZYGEL™ IN FRAGILE X SYNDROME
* ZYNERBA PHARMACEUTICALS - TOPLINE RESULTS FROM CONNECT-FX
TRIAL
EXPECTED LATE IN Q2 OF 2020
Source text for Eikon: ID:nGNXcgKgFx
Further company coverage: ZYNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zynerba Pharmaceuticals
See all newsBrief: Harmony Biosciences Completes Acquisition Of Zynerba Pharmaceuticals
Brief: Harmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba Pharmaceuticals, Inc.
Brief: Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial
U.S. RESEARCH ROUNDUP-Easterly Government Properties, Visa, Zynerba Pharmaceuticals
Zynerba Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary